Impact of Pathologic Complete Response following Neoadjuvant Chemotherapy ± Trastuzumab in Locally Advanced Breast Cancer

Table 1

Baseline demographic and clinical characteristics of the study population (N = 681).

Characteristics	No.	%
Age (years)
Median	44
Range	(38–60)
Menopausal status
Premenopausal	477	70
Postmenopausal	194	27
Clinical tumour stage
II B	185	27
III A	215	32
III B	281	41
Clinical (T) stage
T2	178	26
T3	246	36
T4	257	38
Breast primary tumour size (cm)
Median	7 cm
Range	4–16 cm
Histology
IDC	681	100
Histological grade
Grade II	318	47
Grade III	325	48
Type of breast surgery
Mastectomy	599	88
BCS	82	12
Category of NAC
Anthracycline-based alone	142	21
Anthracycline and taxanes based	380	56
Platinum based	91	13
Taxanes based only	68	10
Hormonal receptor status
ER+/PR+	315	47
ER+/PR−	84	12
ER−/PR−	275	41
Molecular subtypes
ER+/HER2−	278	40.8
ER−/HER2−	156	23
ER+/HER2+	121	17.7
ER−/HER2+	126	18.5
HER2 status by IHC
Negative	434	64
Positive	247	36

No., number; IDC, invasive ductal carcinoma; BCS, breast-conserving surgery; NAC, neoadjuvant chemotherapy; ER, estrogen receptors; PR, progesterone receptors; HER, human epidermal growth factor receptor 2; IHC, immunohistochemistry.